With 0.52 million shares changed hands, the volume of the stock remained heavier than its average volume of 57610.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.28 whereas the lowest price it dropped to was $1.9204. The 52-week range on HOOK shows that it touched its highest point at $10.50 and its lowest point at $1.75 during that stretch. It currently has a 1-year price target of $24.75. Beta for the stock currently stands at 0.71.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HOOK was up-trending over the past week, with a rise of 2.90%, but this was down by -24.42% over a month. Three-month performance dropped to -51.97% while six-month performance fell -66.33%. The stock lost -76.51% in the past year, while it has lost -2.99% so far this year. A look at the trailing 12-month EPS for HOOK yields -3.99 with Next year EPS estimates of -1.93. For the next quarter, that number is -0.66. This implies an EPS growth rate of 71.63% for this year and 20.90% for next year.
Float and Shares Shorts:
At present, 9.66 million HOOK shares are outstanding with a float of 7.19 million shares on hand for trading. On 2024-10-31, short shares totaled 36244.0, which was 37.0 higher than short shares on 1727654400. In addition to Dr. Malte Peters M.D. as the firm’s CEO & Director, Ms. Mary Theresa Coelho M.B.A. serves as its Executive VP, CFO & Director.
Institutional Ownership:
Through their ownership of 0.37162 of HOOK’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, HOOK reported revenue of $4703000.0 and operating income of -$15411000.0. The EBITDA in the recently reported quarter was -$12091000.0 and diluted EPS was -$1.1.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HOOK since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With HOOK analysts setting a high price target of 40.0 and a low target of 2.0, the average target price over the next 12 months is 16.33333. Based on these targets, HOOK could surge 1951.28% to reach the target high and rise by 2.56% to reach the target low. Reaching the average price target will result in a growth of 737.61% from current levels.
Analysts have provided yearly estimates in a range of -$1.85448 being high and -$3.02552 being low. For HOOK, this leads to a yearly average estimate of -$2.44.
